News and Trends 23 Feb 2023
Positive topline data from sepsis trial
Modus Therapeutics AB has published positive top-line data from its phase 1b lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a…